Phathom Pharmaceuticals Profit Margin

Phathom Pharmaceuticals posts a profit margin of 83.49% as of June 2026. That compares with -131.76% in the prior-year period — up 163.4% year over year. That is above the Healthcare sector average of 21.34%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Phathom Pharmaceuticals's profit margin was -131.76%. The latest reading is 83.49% — a 163.4% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 21.34% is typical. Phathom Pharmaceuticals's 83.49% is higher that level. That is roughly 291.3% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Phathom Pharmaceuticals's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 83.49% as of June 2026; use YoY and peer views to separate noise from signal.

Context for PHAT's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 21.34%), and (3) consistency with growth and profitability. This page covers the first two; Phathom Pharmaceuticals's other metric pages and overview cover the third.